239 related articles for article (PubMed ID: 27798861)
21. Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
Wiedmer T; Blank A; Pantasis S; Normand L; Bill R; Krebs P; Tschan MP; Marinoni I; Perren A
Mol Cancer Ther; 2017 Nov; 16(11):2502-2515. PubMed ID: 28729403
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
Invest New Drugs; 2013 Oct; 31(5):1265-74. PubMed ID: 23269537
[TBL] [Abstract][Full Text] [Related]
23. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
Singh M; Couto SS; Forrest WF; Lima A; Cheng JH; Molina R; Long JE; Hamilton P; McNutt A; Kasman I; Nannini MA; Reslan HB; Cao TC; Ho CC; Barck KH; Carano RA; Foreman O; Eastham-Anderson J; Jubb AM; Ferrara N; Johnson L
J Pathol; 2012 Aug; 227(4):417-30. PubMed ID: 22611036
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
Cabebe E; Wakelee H
Drugs Today (Barc); 2006 Jun; 42(6):387-98. PubMed ID: 16845442
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
Khagi S; Saif MW
Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
[TBL] [Abstract][Full Text] [Related]
26. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Yim KL
Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
[TBL] [Abstract][Full Text] [Related]
27. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
29. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
30. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
[TBL] [Abstract][Full Text] [Related]
31. Relevance of angiogenesis in neuroendocrine tumors.
Teulé A; Casanovas O
Target Oncol; 2012 Jun; 7(2):93-8. PubMed ID: 22592949
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
34. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Capdevila J; Tabernero J
Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
[TBL] [Abstract][Full Text] [Related]
35. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.
Pozas J; San Román M; Alonso-Gordoa T; Pozas M; Caracuel L; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597249
[TBL] [Abstract][Full Text] [Related]
36. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
Faivre S; Ronot M; Dreyer C; Serrate C; Hentic O; Bouattour M; Bruno O; Couvelard A; Vilgrain V; Raymond E
Target Oncol; 2012 Jun; 7(2):127-33. PubMed ID: 22585430
[TBL] [Abstract][Full Text] [Related]
37. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
38. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
Barna ME; Uomo I; Pastorello M
JOP; 2013 Jan; 14(1):102-4. PubMed ID: 23306347
[No Abstract] [Full Text] [Related]
39. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
40. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
